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Abstract 
Background-Evidence regarding use of direct oral anticoagulants (DOACs) in the elderly, 
particularly bleeding risks, is unclear despite the presence of greater comorbidities, 
polypharmacy and altered pharmacokinetics in this age group.  
Methods and Results-We performed a systematic review and meta-analysis of randomised 
trials of DOACs (dabigatran, apixaban, rivaroxaban, edoxaban) for efficacy and bleeding 
outcomes compared to VKA (vitamin k antagonists) in elderly participants (aged ≥75 years) 
treated for acute venous thromboembolism or stroke prevention in atrial fibrillation.  
Nineteen studies were eligible for inclusion but only 11 reported data specifically for elderly 
participants. Efficacy in managing thrombotic risks for each DOAC was similar or superior to 
VKA in the elderly. A non-significantly, higher risk of major bleeding than VKA was observed 
with dabigatran 150mg (Odds Ratio 1.18, 95% confidence interval 0.97-1.44) but not with the 
110mg dose. Significantly higher gastrointestinal bleeding risks with dabigatran 150mg (1.78, 
1.35-2.35) and 110mg (1.40, 1.04-1.90) and lower intracranial bleeding risks than VKA for 
dabigatran 150mg (0.43, 0.26-0.72) and dabigatran 110mg (0.36, 0.22-0.61) were also 
observed. A significantly lower major bleeding risk compared to VKA was observed for 
apixaban (0.63, 0.51-0.77), edoxaban 60mg (0.81, 0.67-0.98) and 30mg (0.46, 0.38-0.57) while 
rivaroxaban showed similar risk. 
Conclusion-DOACs demonstrated at least equal efficacy to VKA in managing thrombotic 
risks in the elderly however bleeding patterns were distinct. In particular, dabigatran was 
associated with a higher risk of gastrointestinal bleeding than VKA. Insufficient published data 
for apixaban, edoxaban and rivaroxaban indicates further work is needed to clarify their 
bleeding risks in the elderly. 
Systematic review registration-PROSPERO CRD42014007171 
(www.crd.york.ac.uk/PROSPERO) 
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Introduction 
Advanced age is a significant risk factor for atrial fibrillation (AF) and venous 
thromboembolism (VTE).1, 2  AF prevalence estimates are <0.1% in the population aged <55 
years and rise to over 8% in those aged >80 years.3 Patients with AF have a five-fold greater 
risk of stroke.1, 4 The increased risk of VTE with age is also estimated to double with every 
decade after the age of 40.5, 6 The major complication of VTE is recurrence.7 Anticoagulant 
therapy is essential for managing these thrombotic risks, particularly in an ageing population 
who are at higher risk. 
Vitamin K antagonists (VKA) have until recently been the only oral anticoagulant treatment 
option available for patients. However four direct oral anticoagulants (DOACs), dabigatran, 
rivaroxaban, apixaban and edoxaban have now undergone trials to investigate their harm for 
use and efficacy in the management of thromboembolic risk in AF and acute VTE. They have 
been adopted into clinical practice as they confer certain practical advantages over VKA.8 
They are reported to have less drug-drug and drug-food interactions and have been licensed 
for use without the need for routine monitoring of anticoagulation effect. This is due to their 
predictable pharmacokinetic profiles.9 However, as for VKA, they pose a significant risk of 
bleeding which is complicated further by the lack of a reversal agent.10 
Though several reviews have evaluated the efficacy and harms of DOACs in the general 
population,11, 12 the specific evidence base for their use in the elderly aged ≥75 years remains 
unclear.  The risk of harm with DOACs compared to VKA, in particular bleeding risks, 
warrants clarity given the presence of greater comorbidities, polypharmacy and altered 
pharmacokinetics in the elderly.13 
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We undertook a systematic review and meta-analysis of randomised controlled trials for use 
of the DOACs in the management of AF and acute VTE, where VKA were used as a 
comparator. No randomised controlled trial for DOACs has been conducted thus far that 
involves only elderly participants. Hence, our approach was to evaluate the DOACs for 
efficacy and harms compared to VKA in the elderly participants aged ≥75 years from each 
trial. These results were then put in context by presenting the results from the total trial 
populations (all ages), based on which marketing authorisations for DOACs have been 
granted. 
Methods 
Eligibility Criteria  
We identified all phase II and III randomised controlled trials of the DOACs  (dabigatran 
150mg and 110mg, apixaban, rivaroxaban and edoxaban 60mg and 30mg) in patients being 
treated for acute VTE (deep vein-thrombosis and/or pulmonary embolism) and for stroke 
prevention in AF. We required that studies have a minimum of 3 months patient follow-up 
and used VKA as a comparator. For phase II studies, we extracted data for doses that were 
used for subsequent phase III clinical trials only.  We excluded studies if they were 
extensions of previously completed trials for additional follow-up. 
Search Strategy 
Medline, Embase and CENTRAL (Cochrane central register of controlled trials) were 
searched for articles in English from 22nd November 1993 to 22nd November 2013. The 
search was subsequently updated to June 1st 2014. Search strategies for each database are 
presented in the Supplementary Material. Clinical trial registries were also searched and 
conference proceedings were identified using web of science, scopus and international 
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pharmacy abstracts. Additional studies, including unpublished and grey literature were 
identified by screening reference lists of retrieved studies and review articles. In instances 
where subgroup data for elderly patients aged ≥75 years was unpublished, drug 
manufacturers, authors and relevant regulatory bodies e.g. US FDA (United States Food and 
Drug safety Administration) and EMA (European Medicines Agency) were contacted to 
request the data. The search strategy was checked for appropriateness by a second 
investigator.  
Study Selection  
One reviewer (MS) performed the full search strategy, removed duplicates and selected the 
articles. One of three other independent reviewers (VC, JP, JGD) analysed these selections 
for eligibility of inclusion. Studies were screened based on title and abstract initially, 
following which full texts were obtained and assessed for inclusion. 
Data Extraction  
All data was extracted by two reviewers (MS with VC, JP or JGD) independently into 
standardised forms and entered into Microsoft Excel®.  Data extracted included study details, 
participant details, intervention details (drug name, dose, frequency) and comparator details 
(time in therapeutic range). Data was collected for the subgroup of elderly patients aged ≥75 
years and the total trial population (all ages) for each study. The intention to treat populations 
were used where possible. Primary efficacy outcomes were stroke or systemic embolism for 
AF trials, and recurrent venous thromboembolism for VTE studies. The primary safety 
outcome was pooled major bleeding from both AF and VTE studies. Secondary outcomes 
were gastrointestinal bleeding, intracranial bleeding, clinically relevant bleeding and fatal 
bleeding. Studies were also assessed for potential bias (low, unclear, high) using the 
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Cochrane Collaboration’s risk of bias assessment.14  All disagreements between reviewers 
were resolved by consensus or discussion with a third reviewer. 
Statistical Analyses  
The treatment effect for DOAC compared to VKA was estimated by meta-analyses for each 
drug separately (dabigatran 150mg and 110mg, apixaban, rivaroxaban and edoxaban 60mg 
and 30mg). This was undertaken for elderly participants aged ≥75 years for each outcome of 
interest. It was then repeated for the total trial participants to allow comparison. Data 
synthesis was invariably undertaken using a Peto Odds ratio fixed effect model.15 However, 
when there was high heterogeneity with greater than 4 studies contributing to the estimate; a 
random effects model (DerSimonian and Laird) was used. 16 Use of a random effects model 
to determine estimates is highlighted in the results through use of the annotation “Random 
Effects” in brackets alongside the odds ratio estimate. Study heterogeneity was analysed 
using the I-squared statistic. Sensitivity analysis was undertaken by indication, mean duration 
of patient follow up (<6months vs ≥6months) and where high heterogeneity (>75%) was 
evident. A funnel plot was used to assess publication bias. The manuscript was prepared in 
accordance with the preferred reporting items for systematic reviews and meta-analysis 
(PRISMA).17 All analyses were performed using Review Manager® software (Rev Man 
5.2®). Where only confidence intervals were available for outcomes, event rates were 
calculated using the method detailed by Tierney and colleagues.18 
Results  
Our search identified 19 multi-centred, randomised controlled trials eligible for inclusion 
with 11 reporting data on elderly patients as shown in Supplemental Figure 1. Detailed 
rationale behind exclusion of studies is presented in Supplemental Table S1. Additional 
unpublished data was requested for all 19 studies from manufacturers, authors and regulatory 
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authorities but only data for 4/19 (21.0%) studies was obtained.19-22 Additional data from 
documentation published by regulatory authorities and conference proceedings for 6/19 
(31.6%) studies was also retrieved.19, 20, 23-26  
Study Characteristics 
Eleven phase III and 8 phase II studies consisting of 5 dabigatran trials,24, 27-30 4 apixaban 
trials,26, 31-33 5 rivaroxaban trials,19-23 and 5 edoxaban trials.25, 34-37 All studies used warfarin as 
comparator with 4 studies also allowing use of other VKAs.19, 20, 23, 33 Follow-up periods were 
longest for the phase III AF studies as shown in Table 1. Included studies mostly used 
definitions for major bleeding as per International Society of Thrombosis and Haemostasis,38 
while two phase II studies used a slight variation of this definition.25, 36 Definitions used to 
classify clinically relevant bleeding showed minimal variation and essentially consisted of a 
major bleed or any overt bleeding event that did not meet the criteria for major bleeding but 
led to either hospital admission for bleeding, physician-guided treatment or an alteration in 
therapy. Intracranial and fatal bleeding were both included as part of the major bleeding 
events.  Gastrointestinal bleeding was recorded also as either a major or clinically relevant 
bleed based on independent adjudication in each study.  
Patient Characteristics 
Data was reported for 31,418 elderly participants aged ≥75 years out of a total of 102,479 
participants aged ≥18 years. Mean age ranged from 64.5 to 71.7 years in AF studies and 54.4 
to 59.0 years in VTE studies (Table 2). Mean CHADS2 for AF studies ranged from 1.8 to 3.5 
where reported while percentage of patients recruited with a history of a previous VTE 
ranged from 15.8% to 29.0% in the VTE studies. The Rocket-AF study recruited patients 
with the highest CHADS2 scores of 3.5 in each arm.
22 The dabigatran study, Recover I, was 
the phase III study that recruited the highest percentage of patients with previous VTE for 
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DOAC (25.7%) and VKA (25.4%) therapy respectively.28 All studies permitted usage of 
aspirin if necessary with DOAC, however the percentage of patients on aspirin in individual 
studies was inadequately reported as shown in Supplemental Table S2. 
Risk of Bias Assessment 
Results of the risk of bias assessment for all 19 studies are presented in Figure 1. Eleven 
studies were open-label and at high risk of bias from lack of blinding of patients and 
personnel to the intervention.19, 20, 23-25, 27, 30, 32, 33, 36, 37 However, all studies where reported 
were assessed by blinded adjudicators for the outcomes. Two studies were deemed to be at 
high risk of bias from incomplete outcome data due to unclear attrition.22, 23 In both Rocket-
AF and Einstein-DVT dose,22, 23 93 patients were omitted from analysis due to protocol 
violations. Bibr 1048 was judged to be at risk of other bias because a full publication for the 
trial was not available.24 The funnel plots as shown in Figure 2 for the total population 
indicate we obtained a reasonable expected balance of positive and negative results from the 
included studies. Only 11 studies reported data on the elderly population hence assessment of 
publication bias was challenging. Data was requested from the pharmaceutical companies and 
regulatory bodies where elderly subgroup data had not been reported. However, only limited 
data was made available.   
Outcomes  
Primary Efficacy Outcomes 
Each DOAC was shown to be at least as effective as VKA in the elderly. This was both in 
reducing risk of stroke or systemic embolism in AF, and risk of recurrent venous 
thromboembolism in VTE. Efficacy observed was also similar to that seen in the total 
population (all ages).  
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In AF studies, a significant reduction in risk of stroke or systemic embolism compared to 
VKA was observed for dabigatran 150mg (Odds Ratio 0.66, 95% confidence interval 0.49-
0.90; p=0.009) and apixaban (OR 0.70, 95% CI 0.52-0.93; p=0.01). This significant risk 
reduction was also maintained in the total populations for both DOACs (Figure 3).  
Results in the elderly for all four DOACs in reducing risk of recurrent VTE are shown in 
Figure 4. These estimates were limited by low event rates but did not indicate inferiority 
compared to VKA. Results from the total population also supported non-inferiority to VKA. 
Primary Safety Outcome 
Major bleeding 
In the elderly, a significant reduction in risk of major bleeding compared to VKA was 
observed for for apixaban (OR 0.63, 95% CI 0.51-0.77; p<0.0001), edoxaban 60mg (OR 
0.81, 95% CI 0.67-0.98; p=0.03) and 30mg (OR 0.46, 95% CI 0.38-0.57; p<0.0001). The 
superiority to VKA for these DOACs was also observed in the total population (Figure 5).  
Dabigatran 150mg showed a non-significant, higher risk of major bleeding compared to VKA 
in the elderly (OR 1.18, 95% CI 0.97-1.44; p=0.10); though risk was similar to VKA with the 
110mg dose. In contrast in the total population, a non-significant lower risk than VKA was 
observed with the 150mg dose; while a significantly lower risk was observed with the 110mg 
dose.  
Secondary Outcomes 
Gastrointestinal bleeding 
In the elderly, gastrointestinal bleeding was significantly increased compared to VKA with 
dabigatran 150mg (OR 1.78, 95% CI 1.35-2.35; p<0.0001) and 110mg (OR 1.40, 95% CI 
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1.04-1.90; p=0.03) (Figure 6).  Data regarding risk of gastrointestinal bleeding in the elderly 
for the other DOACs was not published or made available.  
For the total population: the significantly increased risk of gastrointestinal bleeding compared 
to VKA was sustained with dabigatran 150mg, but not with the 110mg dose. In the total 
population, rivaroxaban and edoxaban 60mg also showed a significantly higher risk of 
gastrointestinal bleeding than VKA.  
Intracranial bleeding 
In the elderly, a significant reduction in risk of intracranial bleeding compared to VKA was 
observed for dabigatran 150mg (OR 0.43, 95% CI 0.26-0.72; p=0.001) dabigatran 110mg 
(OR 0.36, 95% CI 0.22-0.61; P=0.0001) and apixaban (OR 0.38, 95% CI 0.24-0.59; 
p<0.0001). A non-significant reduction was also observed for rivaroxaban while data was not 
available for edoxaban in the elderly. 
In the total population all DOACS showed a significantly lower risk of intracranial bleeding 
compared to VKA as shown in Figure 6. 
Clinically Relevant Bleeding 
In the elderly, the risk of clinically relevant bleeding where reported was not significantly 
different for DOACs compared to VKA; except for apixaban, which demonstrated superiority 
to VKA; (OR 0.64, 95% CI 0.54-0.76; p<0.0001; Random Effects).  
In the total population, apixaban, dabigatran 150mg and edoxaban 60mg  and 30mg 
demonstrated superiority to VKA in reducing this risk (Figure 6).  
 11 
 
Fatal Bleeding 
In the elderly, the risk of fatal bleeding where reported was not significantly different for 
DOACs to VKA; except for rivaroxaban which showed superiority (OR 0.53, 95% CI 0.30-
0.93; p=0.03). Data for this outcome was limited by the low number of fatal bleeding events 
in the studies. No data was available for edoxaban. 
In the total population, a significantly reduced risk of fatal bleeding compared to VKA was 
observed for dabigatran 110mg, rivaroxaban, edoxaban 60mg, and edoxaban 30mg (Figure 
6). 
Heterogeneity Assessment and Sensitivity Analysis 
Significant heterogeneity (I2>75%) was found when all four DOACs were pooled together 
and compared to VKA for major bleeding, gastrointestinal bleeding and fatal bleeding. 
Moderate heterogeneity (I2=50-75%) was found for risk of stroke or systemic embolism and 
intracranial bleeding. Sensitivity analysis undertaken by removing the only direct thrombin 
inhibitor, dabigatran, and leaving in the three factor Xa inhibitors showed similar high 
heterogeneity across outcomes. Investigation indicated that this high heterogeneity may be 
due to either differing baseline bleeding risks in the studies or true differences between each 
DOAC which, when pooled, were masked.  This is why results for all four DOACs pooled 
together compared to VKA are not presented. 
There was evidence of statistical heterogeneity in the estimate for risk of major bleeding 
compared to VKA for rivaroxaban in the elderly (I2=82%). This was largely attributable to 
the unusually high number of bleeding events in the VKA arm in Einstein PE compared to 
the other three rivaroxaban AF and VTE studies.  Heterogeneity was also present for the 
estimate for risk of clinically relevant bleeding for apixaban in the total population (I2=81%).  
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Sensitivity analysis did not yield a satisfactory source for this heterogeneity. Hence, a random 
effects model was applied.16 No other outcome estimate produced significant heterogeneity. 
Additional sensitivity analysis by indication and mean duration of patient follow up did not 
significantly alter interpretation of findings in the elderly except in the case of rivaroxaban 
for major bleeding. For rivaroxaban, in AF the major bleeding risk was (OR 1.17, 95%CI 
0.95-1.43) and in VTE it was (OR 0.30, 95%CI 0.15-0.58). 
Discussion  
This systematic review and meta-analysis investigating use of DOACs in AF and VTE has 
shown that they are at least as effective as VKA in the elderly aged ≥75 years. Similar 
efficacy was also seen in the elderly and total trial populations (all ages). The meta-analysis 
of bleeding risks with DOACs has shown them to be distinct to VKA. For the direct thrombin 
inhibitor, dabigatran, risks also appeared to differ for bleeding between elderly and total trial 
populations. Dabigatran 150mg showed a non-significantly higher risk of major bleeding than 
VKA in the elderly. However, in the total population a reduction in major bleeding was 
observed with dabigatran compared to VKA which was significant for the 110mg dose. Two 
of the direct factor Xa inhibitors (apixaban and edoxaban) showed a lower major bleeding 
risk to VKA in both the elderly and total population; while rivaroxaban showed a similar risk.  
Elderly patients taking either dose of dabigatran were at higher risk of gastrointestinal 
bleeding than those on VKA; this risk was also present in the total populations but with the 
150mg dose only. Use of DOACs provided a protective effect compared to VKA against 
intracranial bleeding in the elderly that was consistent with the total population. Results 
where available for clinically relevant bleeding, or fatal bleeding for DOACs did not suggest 
different risks to VKA in the elderly. However, interpretation of these secondary bleeding 
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outcomes in the elderly was limited by the low numbers of elderly patients with bleeding 
events in the studies. This was compounded by the fact that all data requested from 
pharmaceutical manufacturers and regulatory authorities we approached was not made 
available.  
The intention from our protocol was to provide pooled outcome data for all four DOACs 
together versus VKA as well. However, we found significant heterogeneity when the drugs 
were combined for several outcomes. This appeared to be due to either differing baseline 
bleeding risks in the studies or true differences between each drug. Hence, this result was not 
deemed appropriate to present.  
Our choice of the total trial population as our reference group for contextualising the results 
in the elderly was based on guidance in the Cochrane handbook on conducting subgroup 
meta-analysis in trials.14 Comparing two subgroup meta-analyses, ages ≥75 to <75 for 
example, based purely on statistical significance of subgroup results would have been 
misleading as both analyses are likely to have different abilities to detect effects. Hence, we 
did not choose the <75 population as our main reference though we have included the meta-
analysis for the <75 population in the supplementary appendix online. 
The sub-group analysis of the dabigatran Phase III, Re-ly trial suggested that major bleeding 
risk may increase with age for dabigatran.39 Our study has suggested, however that this risk 
increase is not significantly greater than VKA. Dabigatran relies more on renal excretion for 
elimination than the other three DOACs. Given that renal function declines with age, this 
may be a factor for greater bleeding risk.40 However, renal function alone cannot fully 
explain this variation in bleeding risk which is likely to be influenced by other unverified 
age-related factors as well.   
 14 
 
The increased risk of gastrointestinal bleeding and associated mortality with age has been 
well established.41 Use of anticoagulant medication is known to increase this risk further.42 
Gastrointestinal bleeding was found to significantly increase with rivaroxaban, edoxaban 
60mg and dabigatran 150mg compared to VKA in the total population. This risk increased 
further for dabigatran in the elderly. Gastrointestinal bleeding risks with other DOACs in the 
elderly could not be examined due to the lack of availability of data. This was a serious 
concern given that gastrointestinal bleeding has been shown both in this study and previous 
work to be a significant risk with usage of DOACs. 
Use of VKA and advanced age are both strong predictive factors for intracranial bleeding.43 
The protective benefit against intracranial bleeding that the DOACs confer over VKA in the 
general population did not appear to be lost in the elderly. Given that intracranial bleeding is 
one of the major factors responsible for mortality resulting from complications of VKA 
usage, this finding was significant.43 
It is worth noting that the pooled bleeding results in this study are heavily weighted towards 
the large pivotal phase III AF study for each of the four DOACs.22, 26, 27, 35 As a result, the 
respective trial populations in these studies should be considered. Notably, the population in 
the edoxaban (Engage-AF-Timi48),35 and rivaroxaban study (Rocket-AF),22 both had higher 
mean CHADS2 risk scores of 2.8 and 3.5 respectively compared to 2.1 in both the dabigatran 
(Re-ly)27 and apixaban (Aristotle)26 studies. The CHADS2 risk assessment tool can help 
predict risk of stroke in patients with AF,44 and indicated inclusion of a lower risk population 
in Re-ly and Aristotle. Mean time in therapeutic range (TTR) on VKA did vary across the 
four studies (55.0%-64.9%); and Rocket-AF was lowest with 55%. Such deviations in TTR 
are, however also common in clinical practice.45 These differences in the trial populations 
mean comparisons between DOACs can be misleading and were not undertaken here. Until 
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head to head clinical trials comparing the DOACs against one another are conducted, it will 
not be possible to know which DOAC has the best efficacy and harm profile in the elderly or 
total populations. 
Research in Context  
This is the first study that has attained and assessed all available evidence for dabigatran, 
apixaban, rivaroxaban and edoxaban in AF and VTE treatment in the elderly from literature, 
regulatory bodies and drug manufacturers. The DOACs have been tested for other indications 
such as thromboprophylaxis following hip and knee replacements. However, these studies 
used different doses and comparators and hence were not eligible for inclusion.46 
“Real world” data is gradually emerging for the DOACs though such observational data can 
be subject to confounding. 47-49 Studies investigating the risks of dabigatran thus far have 
produced conflicting results.48, 49 A Danish cohort study for example, found significantly 
worse bleeding patterns with dabigatran 110mg in the total population than seen in this 
analysis.49 Two small studies also highlighted how bleeding risks in particular in the elderly 
remain a significant concern with dabigatran.50, 51 As further information emerges from larger 
studies such as the prospective DOAC register in Dresden, harms and benefits for DOACs in 
the elderly will become clearer.52 
Limitations of this study  
Interpretation of subgroup data from clinical trials for elderly patients aged ≥75 years 
requires caution as trials were not initially powered to detect these differences. 
Randomisation in studies was not stratified by age; hence it was not possible to ensure all 
confounders such as concomitant aspirin usage or impaired renal function were balanced 
across arms. Population sizes for primary outcomes, however were reasonably large. Our data 
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was also limited by lack of published results in the public domain or available from 
regulatory authorities and manufacturers. This meant that several summary estimates in the 
elderly were based on only one or two studies. Due to the lack of patient level data, we were 
unable to ascertain the age distribution of our elderly participants and number of ‘frail’ 
elderly patients aged above 80 and 85 years that had actually been included.   
Outcome data on cardiovascular events was not reported. A signal for increased risk of 
myocardial infarction with dabigatran compared to VKA has been previously raised.53 
However, a large post-marketing surveillance study completed by the FDA has not found this 
risk to be significant.54 
In the VTE studies, it was common for patients to receive several days (median 2-9 days) of a 
heparin before beginning treatment with either a DOAC or VKA.28, 29, 34 In Amplify, 
Einstein- DVT and Einstein-PE they received a higher dose of oral anticoagulant for a short 
period prior to initiation of standard DOAC dose.19, 20, 31 Also, as bleeding definitions were 
not mutually exclusive within trials; some estimates of risk by bleeding classification were 
difficult to interpret. These factors could ultimately affect the precision of bleeding estimates.  
Follow-up did vary between studies, however all had at least 3 months and covered the initial 
period during which harm has been found to be highest with usage of anticoagulants.55 
Conclusion 
DOACs showed at least equal efficacy to VKA in the elderly for acute VTE and AF. 
However, bleeding patterns seen with DOACs were different. Dabigatran, in particular, 
showed a significantly higher risk of gastrointestinal bleeding and a non-significantly higher 
major bleeding risk than VKA. This suggests that caution is required in prescribing where 
there may be concomitant risk factors for gastrointestinal bleeding in the elderly.  A benefit 
of reduced intracranial bleeding was seen with dabigatran, apixaban and rivaroxaban.  
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Insufficient published data for apixaban, edoxaban and rivaroxaban meant all bleeding risks, 
particularly gastrointestinal risks, could not be fully explored in the elderly.  Better 
availability of unpublished trial data and more research is needed to elucidate risks further. 
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Table 1 Characteristics of included studies for DOACs in atrial fibrillation and venous 
thromboembolism. 
Study Indication Standard Dose Phase Duration/Median Follow 
up* (months) 
DABIGATRAN         
Bibr 1048, 200524 AF 110mg BD or 150mg BD II 3 
Petro, 200730 AF 150mg BD extracted II 3 
Re-ly, 200927 AF 110mg or 150mg BD  III 24* 
Recover I, 201028 VTE 150mg BD III 6 
Recover II, 201329 VTE 150mg BD III 6 
APIXABAN        
Aristotle, 201126 AF 5mg BD  III 21.6* 
Aristotle-J, 201132 AF 5mg BD extracted II 3 
Botticelli-DVT, 200833 VTE 5mg BD  II 3 
Amplify, 201331 VTE 10mg BD for 7 days then 5mg 
BD 
III 6 
RIVAROXABAN     
Rocket-AF, 201122 AF 20mg OD III 23.2* 
J-Rocket AF, 201121 AF 15mg OD III 30 
Einstein-DVT Dose Study, 
200823 
VTE 20mg OD extracted II 3 
Einstein-DVT, 201019 VTE 15mg BD for 21 days then 
20mg OD 
III 3,6 or 12 
Einstein-PE, 201220 VTE 15mg BD for 21 days then 
20mg OD 
III 3,6 or 12 
EDOXABAN        
Edox-P2, 201036 AF 30mg or 60mg OD extracted II 3 
Edox-P2A, 201025 AF 30mg OD or 60mg OD   II 3 
Edox-J, 201237 AF 30mg or 60mg OD extracted II 3 
Engage-AF-Timi 48, 201335 AF 30mg OD or 60mg OD   III 33.6* 
Hokusai-VTE, 201334 VTE 60mg OD III 3 to 12 
OD= Once daily 
BD=Twice daily 
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Table 2 Patient Characteristics in included studies for DOACs in atrial fibrillation and venous thromboembolism. 
Study Total Participants Participants ≥75 Mean Age (SD) Men% CHADS2 (SD) Previous VTE (%) 
 DOAC VKA DOAC VKA DOAC VKA DOAC VKA DOAC VKA DOAC VKA 
DABIGATRAN             
Bibr 1048, 
200524 
104 62 NA NA 69.0 (8.4)  67.4 (8.8) 85.6 91.9 NA NA NA NA 
Petro,  
200730 
169 70 NA NA 70.0 (8.1) 69.0 (8.3) 81.3 84.3 NA NA NA NA 
Re-ly,  
200927 
12091 6022 4815 2423 71.4 (8.7)   71.6 (8.6) 63.7 63.3 2.1(1.1) 2.1(1.1) NA NA 
Recover I, 
201028 
1274 1265 NA NA 55.0 (15.8)  54.4 
(16.2) 
58.0 58.9 NA NA 327 (25.7) 322 
(25.4) 
Recover II, 
201329 
1279 1289 NA NA 54.7 (16.2) 55.1 
(16.3) 
61.0 60.2 NA NA 247 (19.3) 203 
(15.8) 
APIXABAN             
Aristotle, 
201126 
9120 9081 2850 2828 69.1(9.6) 69.0 (9.7) 64.5 65.0 2.1 (1.1) 2.1 (1.1) NA NA 
Aristotle-J, 
201132 
74 74 45 23 70.0 (8.1) 71.7 (7.0) 82.4 81.1 2.1 1.9 NA NA 
Botticelli-
DVT,200833 
130 128 NA NA 56.0 (14.0) 59.0 
(16.0) 
64.0 63.0 NA NA 37 (28.5) 31 (24.2) 
Amplify, 201331 2691 2704 398 370 57.2 (16.0) 56.7 
(16.0) 
58.3 59.1 NA NA 463 (17.2) 409 
(15.1) 
RIVAROXABAN             
Rocket-AF, 
201122 
7131 7133 3082 3082 71.2 (9.4) 71.2 (9.4) 60.3 60.3 3.5 (0.9) 3.5 (0.9) NA NA 
J-Rocket AF, 
201121 
640 640 252 246 71.0 (8.3) 71.2 (7.9) 82.9 78.2 3.3 3.2 NA NA 
 
 
 
Einstein-DVT 
Dose Study, 
200823 
136 137 NA NA 58.0 57.0 47.0 53.0 NA NA 28 (21.0) 
 
 
40 (29.0) 
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Study Total Participants Participants ≥75 Mean Age (SD) Men% CHADS2 (SD) Previous VTE (%) 
 DOAC VKA DOAC VKA DOAC VKA DOAC VKA DOAC VKA DOAC VKA 
 
Einstein-DVT, 
201019 
1731 1718 215 225 55.8 (16.4) 56.4 
(16.3) 
57.4 56.3 NA NA 336 (19.4) 330 
(19.2) 
Einstein-PE, 
201220 
2419 2413 441 402 57.9 (7.3) 57.5 (7.2) 54.1 51.7 NA NA 455 (18.8) 489 
(20.3) 
EDOXABAN             
Edox-P2, 201036 470 251 NA NA 65.0 (8.6)  66.0 (8.5) 63.0 60.4 NA NA NA NA 
Edox-P2A, 
201025 
159 76 21 10 65.4 (8.4)  64.5 (9.5) 66.6 62.7 1.9(1.0) 1.8(1.1) NA NA 
Edox-J, 201237 267 134 77 35 68.9 68.8 73.2 82.9 2.0 2.2 NA NA 
Engage-AF-Timi 
48, 201335 
14069 7036 5654 2820 70.6(9.4) 70.5(9.4) 61.6 62.5 2.8(1.0) 
and 
2.8(1.0) 
2.8(1.0) NA NA 
Hokusai-VTE, 
201334 
4143 4149 560 544 55.7 (16.3) 55.9 
(16.2) 
57.3 57.2 NA NA 784 (19.0) 736 
(17.9) 
NA= Not available 
SD= Standard Deviation 
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Figure 1 Summary of risk of bias assessment. 
Green(+) =Low bias risk; Red (-)=High bias risk; Yellow(?)=Unclear bias risk 
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  Funnel Plot for risk of major bleeding in the elderly 
Funnel Plot for risk of major bleeding in the total population 
Figure 2 Funnel Plot Comparison for risk of major bleeding in the elderly (top) and total population 
(below). 
*Note: Y axis scales differ between plots above. 
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Total Population (all ages) Elderly Population aged≥75 
years
Figure 3 Risk of stroke or systemic embolism in atrial fibrillation studies in elderly (left) and total population (right). 
*Event numbers for Engage-AF-Timi 48 in elderly have been estimated from published confidence intervals.  
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Total Population (all ages) Elderly Population aged≥75 
years
 
Figure 4 Risk of recurrent venous thromboembolism in venous thromboembolism studies in elderly (left) and total population (right). 
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Elderly Population aged≥75 
years
Total Population (all ages) 
Figure 5 Risk of major bleeding in elderly (left) and total population (right). 
*Event numbers for Engage-AF-Timi-48 and J-Rocket AF in the elderly have been estimated from published confidence intervals.  
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Figure 6 Risk of secondary outcomes in elderly (left) and total population (right).                                                                                                                                               
GIB= Gastrointestinal bleeding; ICB = Intracranial Bleeding; CRB= Clinically Relevant Bleeding; FB= Fatal Bleeding                                                                                              
*CRB estimate was only estimate derived using a random effects model. **Note: Full Forest Plots for each estimate above are available in the supplementary appendix. 
